Mount Sinai Showcases Innovative Cancer Research at 2025 AACR Annual Meeting in Chicago
Researchers at the Mount Sinai Health System will present groundbreaking science at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place Friday through Wednesday, April 25-30, at the McCormick Place Convention Center in Chicago. Their work spans therapeutic innovations, advances in cancer biology, and developments in data-driven precision oncology. The AACR Annual Meeting is one of the largest gatherings of cancer researchers in the world, spotlighting the latest discoveries and breakthroughs across the cancer continuum.
“The AACR Annual Meeting is one of the most important global stages for showcasing progress in cancer science, and I’m incredibly proud of the breadth and depth of Mount Sinai’s contributions this year,” said Ramon E. Parsons, MD, PhD, Director of The Tisch Cancer Institute and Dean for Cancer Research at the Icahn School of Medicine at Mount Sinai. “From novel therapeutic strategies to advanced data science approaches and translational research that can reach patients faster, our investigators are helping define the future of cancer care. We’re proud to see Mount Sinai researchers at the forefront of oncology innovation. Their work reflects our deep commitment to advancing science that transforms cancer care and outcomes.”
Notable oral presentations from Mount Sinai faculty at the 2025 AACR Annual Meeting:
New Approaches to Target Undruggable Proteins
Jian Jin, PhD
Wednesday, April 30, 10:15-11:45 am
Room S100 A (Grand Ballroom A), McCormick Place South (Level 1)
https://www.abstractsonline.com/pp8/#!/20273/presentation/589
The Seed AND the Soil: How Cancer-Induced and Aging-Related Immune Dysregulation Collide to Promote Lung Cancer
Thomas Marron, MD, PhD
Sunday, April 27, 1 pm
Room S100 BC (Grand Ballroom BC), McCormick Place South (Level 1)
https://www.abstractsonline.com/pp8/#!/20273/presentation/8654
Dr. Marron is also chairing the Dharma Master Jiantai Advances in Lung Cancer Research Session: Aging and Environmental Cues Drive Lung Cancer Development and Spread
https://www.abstractsonline.com/pp8/#!/20273/session/81
CDK Regulation of the RNAPII Transcription Cycle: Molecular Mechanisms and Therapeutic Opportunities
Robert Fisher, MD, PhD
Saturday, April 26, 12:30-1pm
Room S402, McCormick Place South (Level 4)
https://www.abstractsonline.com/pp8/#!/20273/presentation/8648
In addition, Nina Bhardwaj, MD, PhD is chairing a special session about approaches to overcome the multiple barriers to adoptive T cell therapies (ACT, including CAR T cells) in solid tumors:
Advances in Gene and Cellular Therapy
Friday, April 25, 3-4:30 pm
Room S100 A (Grand Ballroom A), McCormick Place South (Level 1)
https://www.abstractsonline.com/pp8/#!/20273/session/240
Posters include:
L2S2: Chemical Perturbation and CRISPR KO LINCS L1000 Signature Search Engine
Avi Ma’ayan, PhD
Sunday, April 27, 2-5 pm
Poster Section 46
https://www.abstractsonline.com/pp8/#!/20273/presentation/3436
Hgrn-Chear: Human Transcription Factor Regulatory Network With a Knowledge Graph Interactive User Interface
Avi Ma’ayan, PhD
Tuesday, April 29, 2-5 pm
Poster Section 46
https://www.abstractsonline.com/pp8/#!/20273/presentation/3532
Sc2dat: Workflow for Targeting Tumor Subpopulations of Single Cells
Avi Ma’ayan, PhD
Tuesday, April 29, 2-5 pm
Poster Section 46
https://www.abstractsonline.com/pp8/#!/20273/presentation/3517
Mechanistic Rationale for Combination of RAF/MEK Glue Avutometinib With a Pan-RAF Inhibitor for RAS-Mutant Tumor-Selective Therapy
Bijaya Gaire, PhD (Poulikakos Laboratory)
Wednesday, April 30, 9 am-12 pm
Poster Section 51
https://www.abstractsonline.com/pp8/#!/20273/presentation/10012
A Gated Hydrophobic Funnel Within BAX Binds Long-Chain Alkenals to Potentiate Pro-Apoptotic Function
Jerry Edward Chipuk, PhD
Monday, April 28, 9 am-12 pm
Poster Section 9
https://www.abstractsonline.com/pp8/#!/20273/presentation/1255
Revealing the Influence of Reprogrammed PI3K and Glucose Metabolism on the Progression of Hormone-Refractory and Metastatic Prostate Cancer
Prathiksha Prabhakara alva, PhD (Lab of Goutam Chakraborty, PhD)
Tuesday, April 29, 2-5 pm
Session Title: Metabolic Reprogramming
Poster Section 12
https://www.abstractsonline.com/pp8/#!/20273/presentation/4260
Investigating the Effect of Male-Specific Lysine Demethylase 5D Alteration on Oncogenic Behavior in Human Prostate Cancer Cells
Sarah Ann S. King MSc, PhD (Lab of Goutam Chakraborty, PhD)
Wednesday, April 30, 9 am-12 pm
Poster Section 13
https://www.abstractsonline.com/pp8/#!/20273/presentation/6780
Molecular Insights and Biology of Low-PSA High-Risk Prostate Cancer
Nabila Zaman, MS (Lab of Goutam Chakraborty, PhD)
Wednesday, April 30, 9 am-12 pm
Poster Section 45
https://www.abstractsonline.com/pp8/#!/20273/presentation/5700
Mechanism of Tumor-Selective Inhibition of Dimeric RAF by a Type 1 RAF Inhibitor
Mathieu Desaunay, PhD (Poulikakos Laboratory)
Tuesday, April 29, 9 am-12 pm
Poster Section 52
https://www.abstractsonline.com/pp8/#!/20273/presentation/10044
Secreted PTEN-Long Downregulates PI3K Signaling and PD-L1 and Promotes Anti-Tumor Antigen-Presenting Cell Functions to Cause Regressions of Mouse Tumors
Tiphaine Martin, PhD (Parsons Laboratory)
Monday, April 28, 2-5 pm
Poster Section 54
https://www.abstractsonline.com/pp8/#!/20273/presentation/10067
For more information about 2025AACR visit https://www.aacr.org/meeting/aacr-annual-meeting-2025/
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.